Your browser doesn't support javascript.
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions.
Tanasijevic, Anna M; Revette, Anna; Klepin, Heidi D; Zeidan, Amer; Townsley, Danielle; DiNardo, Courtney D; Sebert, Marie; DeZern, Amy E; Stone, Richard M; Magnavita, Emily S; Chen, Richard; Sekeres, Mikkael A; Abel, Gregory A.
  • Tanasijevic AM; Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Revette A; Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Klepin HD; Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Zeidan A; Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA.
  • Townsley D; Oncology at MedImmune/AstraZeneca, Gaithersburg, MD, USA.
  • DiNardo CD; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sebert M; Service de Hematologie Seniors, Hospital Saint Louis, Universit Paris 7, Paris, France.
  • DeZern AE; Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA.
  • Stone RM; Department of Medical Oncology, Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Magnavita ES; Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Chen R; Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sekeres MA; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Abel GA; Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Leuk Lymphoma ; 61(12): 2900-2904, 2020 12.
Article in English | MEDLINE | ID: covidwho-647011
ABSTRACT
The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COVID-19 era, where decreases in blood donations have stressed the blood supply. In March 2018, using a modified Delphi method, we convened a panel of 13 expert MDS clinicians for three iterative rounds to discuss a minimum safe Hb for this population. While the panel was unable to reach the pre-set consensus of 75% for a specific Hb threshold, there was 100% consensus that it be no greater than 7.5 g/dL. Our data suggest that, given no end-organ effects of anemia, patients with MDS can safely forgo transfusions with a Hb of 7.5 g/dL or higher.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Transfusion / Myelodysplastic Syndromes / Hemoglobins / Practice Guidelines as Topic / Anemia Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Leuk Lymphoma Journal subject: Hematology / Neoplasms Year: 2020 Document Type: Article Affiliation country: 10428194.2020.1791854

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Transfusion / Myelodysplastic Syndromes / Hemoglobins / Practice Guidelines as Topic / Anemia Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Leuk Lymphoma Journal subject: Hematology / Neoplasms Year: 2020 Document Type: Article Affiliation country: 10428194.2020.1791854